Literature DB >> 16317103

Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status.

Mia Thorsélius1, Alexander Kröber, Fiona Murray, Ulf Thunberg, Gerard Tobin, Andreas Bühler, Dirk Kienle, Emilia Albesiano, Rossana Maffei, Lan-Phuong Dao-Ung, James Wiley, Juhani Vilpo, Anna Laurell, Mats Merup, Göran Roos, Karin Karlsson, Nicholas Chiorazzi, Roberto Marasca, Hartmut Döhner, Stephan Stilgenbauer, Richard Rosenquist.   

Abstract

We recently reported that Swedish VH3-21-using chronic lymphocytic leukemia (CLL) patients showed restricted immunoglobulin gene features and poor prognosis despite VH mutation status. To investigate this further, we analyzed the VH and VL gene rearrangements in 90 VH3-21+ patients from Sweden, Germany, Italy, United States, Finland, and Australia and correlated these data with survival and other prognostic markers. Sixty-three percent exhibited mutated VH genes and 37% unmutated VH genes. Fifty (56%) patients displayed a short and homologous heavy-chain CDR3, many of these with the amino acid motif DANGMDV. Also, a highly biased Vlambda2-14 use was evident in 72% of patients with a restricted light-chain CDR3, QVWDS(S/G)SDHPWV. Combined restricted heavy- and light-chain CDR3s were found in patients from all included countries. Although VH3-21+ CLLs have a remarkably predominant lambda expression, analyses of kappa deleting element indicated a conserved light-chain rearrangement order. The overall survival was poor in the VH3-21+ cohort (median survival, 88 months), with no significant difference in relation to mutation status or CDR3 homology. High ZAP-70 and CD38 expression was found in both mutated and unmutated VH3-21+ cases as well as a slight increase of 11q-aberrations. In summary, highly restricted B-cell receptors and worse outcome characterize VH3-21+ CLLs independent of geographic origin and mutation status.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16317103     DOI: 10.1182/blood-2005-06-2227

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

Review 1.  Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Authors:  Leopold Sellner; Sascha Dietrich; Peter Dreger; Hanno Glimm; Thorsten Zenz
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation.

Authors:  Jacob Glanville; Tracy C Kuo; H-Christian von Büdingen; Lin Guey; Jan Berka; Purnima D Sundar; Gabriella Huerta; Gautam R Mehta; Jorge R Oksenberg; Stephen L Hauser; David R Cox; Arvind Rajpal; Jaume Pons
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

3.  High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.

Authors:  Millaray Marincevic; Nicola Cahill; Rebeqa Gunnarsson; Anders Isaksson; Mahmoud Mansouri; Hanna Göransson; Markus Rasmussen; Mattias Jansson; Fergus Ryan; Karin Karlsson; Hans-Olov Adami; Fred Davi; Jesper Jurlander; Gunnar Juliusson; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

4.  Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.

Authors:  David Oscier; Rachel Wade; Zadie Davis; Alison Morilla; Giles Best; Sue Richards; Monica Else; Estella Matutes; Daniel Catovsky
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

5.  Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2010-12       Impact factor: 9.941

6.  Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.

Authors:  Emanuela M Ghia; Sonia Jain; George F Widhopf; Laura Z Rassenti; Michael J Keating; William G Wierda; John G Gribben; Jennifer R Brown; Kanti R Rai; John C Byrd; Neil E Kay; Andrew W Greaves; Thomas J Kipps
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

7.  B-cell clones as early markers for chronic lymphocytic leukemia.

Authors:  Ola Landgren; Maher Albitar; Wanlong Ma; Fatima Abbasi; Richard B Hayes; Paolo Ghia; Gerald E Marti; Neil E Caporaso
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

8.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Authors:  S Jeromin; S Weissmann; C Haferlach; F Dicker; K Bayer; V Grossmann; T Alpermann; A Roller; A Kohlmann; T Haferlach; W Kern; S Schnittger
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

9.  Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?

Authors:  Carol Moreno; Emili Montserrat
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

10.  Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.

Authors:  Dirk Kienle; Axel Benner; Carolin Läufle; Dirk Winkler; Christof Schneider; Andreas Bühler; Thorsten Zenz; Annett Habermann; Ulrich Jäger; Peter Lichter; Riccardo Dalla-Favera; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.